Login to Your Account

Pharma relying on external innovation, report shows

By Nuala Moran
Staff Writer

Monday, February 3, 2014

LONDON – Pharma’s dependence on biotechs and academics for innovation is highlighted in an analysis of the 94 novel drugs approved in Europe from 2010 to 2012, which shows that while 87 percent of the approvals were granted to pharmaceutical companies, more than half of the products had their origins outside corporate laboratories.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription